Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 7, 2013, Pages 781-794

  Martiskainen, Henna ^a   Haapasalo, Annakaisa ^a   Kurkinen, Kaisa Ma ^a   Pihlajamäki, Jussi ^a   Soininen, Hilkka ^a   Hiltunen, Mikko ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

amyloid clearance; Alzheimer's disease; Apolipoprotein E4; Apolipoprotein receptors; Blood brain barrier; Low density lipoprotein receptor related protein 1; Therapeutic targets

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTOFERRIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; ENZYME METABOLISM; GENETIC ASSOCIATION; HUMAN; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; VASCULAR SMOOTH MUSCLE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1;

EID: 84879058565     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.789862     Document Type: Review

References (127)

1. Mayeux R, Stern Y. Epidemiology of alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(8): 1-18
2. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41(4): 479-86
3. Braak H, Braak E. Neuropathological staging of alzheimer-related changes. Acta Neuropathol 1991; 82(4): 239-59
4. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115(6): 1449-57 (Pubitemid 40814649)
5. Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis-lessons from amyloid precursor protein processing. J Neurochem 2011; 117(5): 779-96
6. St George-Hyslop P, Fraser PE. Assembly of the presenilin gamma-/epsilon-secretase complex. J Neurochem 2012; 120(Suppl 1): 84-8
7. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's abeta peptide: the many roads to perdition. Neuron 2004; 43(5): 605-8 (Pubitemid 39179722)
8. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000; 924: 17-25 (Pubitemid 32050177)
9. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 2011; 108(14): 5819-24
10. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123): 921-3 (Pubitemid 23275809)
11. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43(8): 1467-72 (Pubitemid 23230526)
12. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39(1): 17-23 (Pubitemid 46026496)
13. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A metaanalysis. APOE and alzheimer disease meta analysis consortium. JAMA 1997; 278(16): 1349-56
14. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nat Genet 1994; 7(2): 180-4 (Pubitemid 24174658)
15. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE epsilon2 Lancet 1994; 343(8910): 1432-3 (Pubitemid 24167530)
16. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14(1): 55-61 (Pubitemid 26301547)
17. Sen A, Alkon DL, Nelson TJ. Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J Biol Chem 2012; 287(19): 15947-58
18. Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 2012; 32(43): 15181-92
19. Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008; 118(12): 4002-13 . This paper first defined the differential effect of ApoE isoforms on Ab clearance.
20. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27(5): 909-18 (Pubitemid 46659038)
21. Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006; 7(11): 850-9 (Pubitemid 44624177)
22. May P, Herz J. LDL receptor-related proteins in neurodevelopment. Traffic 2003; 4(5): 291-301 (Pubitemid 36582631)
23. Cam JA, Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 2006; 1: 8
24. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 2012; 85(1): 19-28
25. Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003; 5(1): 1-8 (Pubitemid 36422845)
26. Holtzman DM, Herz J, Bu G. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(3): a006312
27. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88(3): 887-918
28. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10(5): 333-44
29. Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108(6): 779-84 (Pubitemid 32880284)
30. Boucher P, Herz J. Signaling through LRP1: protection from atherosclerosis and beyond. Biochem Pharmacol 2011; 81(1): 1-5
31. Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-golgi compartment. EMBO J 1990; 9(6): 1769-76
32. Willnow TE, Moehring JM, Inocencio NM, et al. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Biochem J 1996; 313(Pt 1): 71-6 (Pubitemid 26013427)
33. Croy JE, Shin WD, Knauer MF, et al. All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands. Biochemistry 2003; 42(44): 13049-57 (Pubitemid 37385837)
34. Obermoeller-McCormick LM, Li Y, Osaka H, et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 2001; 114(Pt 5): 899-908 (Pubitemid 32266261)
35. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106(12): 1489-99 (Pubitemid 32038587)
36. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12(12): 723-38
37. Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 2000; 6(7): 718-19 (Pubitemid 30469391)
38. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330(6012): 1774
39. Gylys KH, Fein JA, Tan AM, Cole GM. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem 2003; 84(6): 1442-51 (Pubitemid 36343610)
40. Fuentealba RA, Liu Q, Zhang J, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 2010; 5(7): e11884
41. Zerbinatti CV, Wahrle SE, Kim H, et al. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 2006; 281(47): 36180-6 (Pubitemid 46041352)
42. Hu X, Crick SL, Bu G, et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 2009; 106(48): 20324-9
43. Ji ZS, Mullendorff K, Cheng IH, et al. Reactivity of apolipoprotein E4 and amyloid beta peptide: Lysosomal stability and neurodegeneration. J Biol Chem 2006; 281(5): 2683-92 (Pubitemid 43845731)
44. Ji ZS, Miranda RD, Newhouse YM, et al. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem 2002; 277(24): 21821-8 (Pubitemid 34952334)
45. Belinson H, Lev D, Masliah E, Michaelson DM. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci 2008; 28(18): 4690-701
46. Li J, Kanekiyo T, Shinohara M, et al. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 2012; 287(53): 44593-601
47. Kanekiyo T, Liu CC, Shinohara M, et al. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-beta. J Neurosci 2012; 32(46): 16458-65
48. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18(2): 253-66 (Pubitemid 351430402)
49. Wilhelmus MM, Otte-Holler I, van Triel JJ, et al. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 2007; 171(6): 1989-99
50. Ruzali WA, Kehoe PG, Love S. Influence of LRP-1 and apolipoprotein E on amyloid-beta uptake and toxicity to cerebrovascular smooth muscle cells. J Alzheimers Dis 2013; 33(1): 95-110
51. Ruzali WA, Kehoe PG, Love S. LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status. Neurosci Lett 2012; 525(2): 123-8
52. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004; 10(7): 719-26 (Pubitemid 38937637)
53. Carlo AS, Gustafsen C, Mastrobuoni G, et al. The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain. J Neurosci 2013; 33(1): 358-70
54. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of abeta isoforms. Neuron 2004; 43(3): 333-44 (Pubitemid 39061126)
55. Daneman R. The blood-brain barrier in health and disease. Ann Neurol 2012; 72(5): 648-72
56. Shiiki T, Ohtsuki S, Kurihara A, et al. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 2004; 24(43): 9632-7 (Pubitemid 39441517)
57. Pflanzner T, Janko MC, Andre-Dohmen B, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 2011; 32(12): 2323; e1, 2323.11
58. Sagare AP, Deane R, Zlokovic BV. Low-density lipoprotein receptor-related protein 1: a physiological abeta homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther 2012; 136(1): 94-105
59. Zlokovic BV, Deane R, Sagare AP, et al. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem 2010; 115(5): 1077-89
60. Bachmeier C, Paris D, Beaulieu-Abdelahad D, et al. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis 2013; 11(1): 13-21
61. Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem 2001; 276(21): 18000-6
62. Urich E, Lazic SE, Molnos J, et al. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 2012; 7(5): e38149
63. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994; 63: 601-37
64. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 2006; 56(3): 246-52 (Pubitemid 44572534)
65. Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 2010; 113(5): 1356-63
66. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 2008; 30(1): 94-102
67. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an alzheimer disease mouse model. J Clin Invest 2005; 115(11): 3285-90 (Pubitemid 41567593)
68. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010; 77(5): 715-23
69. Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996; 93(9): 4229-34
70. Carro E, Spuch C, Trejo JL, et al. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 2005; 25(47): 10884-93 (Pubitemid 41692618)
71. Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010; 22(3): 849-59
72. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9(7): 907-13 (Pubitemid 36889934)
73. von Arnim CA, Kinoshita A, Peltan ID, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 2005; 280(18): 17777-85 (Pubitemid 41389016)
74. Liu Q, Zhang J, Tran H, et al. LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 2009; 4: 17; 1326-4-17
75. Liang F, Jia J, Wang S, et al. Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J Clin Neurosci 2012; 20: 3): 357-61
76. Quinn KA, Grimsley PG, Dai YP, et al. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 1997; 272(38): 23946-51 (Pubitemid 27410977)
77. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007; 13(9): 1029-31 (Pubitemid 47517512)
78. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier abeta clearance in Alzheimer's disease. Curr Pharm Des 2008; 14(16): 1601-5 (Pubitemid 352002987)
79. Charlton MR. Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab 1996; 10(4): 617-35 (Pubitemid 27056596)
80. Ghiso J, Shayo M, Calero M, et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 2004; 279(44): 45897-908 (Pubitemid 39491582)
81. Tamaki C, Ohtsuki S, Iwatsubo T, et al. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 2006; 23(7): 1407-16 (Pubitemid 43993806)
82. Mackic JB, Bading J, Ghiso J, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 2002; 38(6): 303-13 (Pubitemid 36398252)
83. Mackic JB, Weiss MH, Miao W, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998; 70(1): 210-15 (Pubitemid 28020845)
84. Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 2007; 72(4): 850-5 (Pubitemid 47481408)
85. Smith CC, Betteridge DJ. Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 2004; 367(1): 48-50 (Pubitemid 39078782)
86. Sharman MJ, Morici M, Hone E, et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 2010; 21(2): 403-9
87. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007; 2: 22
88. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286(5440): 735-41
89. Parvathy S, Hussain I, Karran EH, et al. Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. Biochemistry 1999; 38(30): 9728-34
90. Pasternak SH, Bagshaw RD, Guiral M, et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem 2003; 278(29): 26687-94 (Pubitemid 36876814)
91. Ray WJ, Yao M, Mumm J, et al. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of notch. J Biol Chem 1999; 274(51): 36801-7
92. Rechards M, Xia W, Oorschot VM, et al. Presenilin-1 exists in both pre-and post-golgi compartments and recycles via COPI-coated membranes. Traffic 2003; 4(8): 553-65 (Pubitemid 36896547)
93. Annaert WG, Levesque L, Craessaerts K, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol 1999; 147(2): 277-94 (Pubitemid 29496338)
94. Cam JA, Zerbinatti CV, Li Y, Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J Biol Chem 2005; 280(15): 15464-70 (Pubitemid 40562905)
95. Ulery PG, Beers J, Mikhailenko I, et al. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 2000; 275(10): 7410-15 (Pubitemid 30146296)
96. Zerbinatti CV, Wozniak DF, Cirrito J, et al. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 2004; 101(4): 1075-80 (Pubitemid 38160586)
97. Knauer MF, Orlando RA, Glabe CG. Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). Brain Res 1996; 740(1-2): 6-14 (Pubitemid 26411277)
98. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995; 82(2): 331-40
99. Pietrzik CU, Busse T, Merriam DE, et al. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 2002; 21(21): 5691-700 (Pubitemid 35315269)
100. Pietrzik CU, Yoon IS, Jaeger S, et al. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 2004; 24(17): 4259-65 (Pubitemid 38620802)
101. Rebeck GW, Moir RD, Mui S, et al. Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res Mol Brain Res 2001; 87(2): 238-45 (Pubitemid 32195475)
102. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 1998; 273(50): 33556-60 (Pubitemid 29005740)
103. Klug W, Dietl A, Simon B, et al. Phosphorylation of LRP1 regulates the interaction with Fe65. FEBS Lett 2011; 585(20): 3229-35
104. Ando K, Iijima KI, Elliott JI, et al. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem 2001; 276(43): 40353-61
105. Tanahashi H, Tabira T. Molecular cloning of human Fe65L2 and its interaction with the Alzheimer's beta-amyloid precursor protein. Neurosci Lett 1999; 261(3): 143-6 (Pubitemid 29104965)
106. Sabo SL, Lanier LM, Ikin AF, et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem 1999; 274(12): 7952-7
107. Santiard-Baron D, Langui D, Delehedde M, et al. Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load. J Neurochem 2005; 93(2): 330-8 (Pubitemid 40547490)
108. Wahler A, Beyer AS, Keller IE, et al. Engulfment adapter PTB domain containing 1 (GULP1) is a nucleocytoplasmic shuttling protein and transactivationally active together with low density lipoprotein receptor-related protein 1 (LRP1). Biochem J 2013; 450(2): 333-43
109. Alvira-Botero X, Perez-Gonzalez R, Spuch C, et al. Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Mol Cell Neurosci 2010; 45(3): 306-15
110. Lakshmana MK, Chen E, Yoon IS, Kang DE. C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. J Cell Mol Med 2008; 12(6B): 2665-74
111. Lakshmana MK, Yoon IS, Chen E, et al. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J Biol Chem 2009; 284(18): 11863-72
112. Lakshmana MK, Hayes CD, Bennett SP, et al. Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain. FASEB J 2012 May; 26(5): 2072-83
113. Lakshmana MK, Chung JY, Wickramarachchi S, et al. A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J 2010; 24(1): 119-27
114. Ye S, Huang Y, Mullendorff K, et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005; 102(51): 18700-5 (Pubitemid 43011289)
115. Biere AL, Ostaszewski B, Zhao H, et al. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol Dis 1995; 2(3): 177-87
116. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006; 112(4): 405-15 (Pubitemid 44469161)
117. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106(9): 1159-66
118. Moon JH, Kang SB, Park JS, et al. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor atorvastatin and hepatic LRP1 expression. Metabolism 2011; 60(7): 930-40
119. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35(11 Suppl 1): 2628-31 (Pubitemid 39458354)
120. Shinohara M, Sato N, Kurinami H, et al. Reduction of brain beta-amyloid (abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and abeta clearance. J Biol Chem 2010; 285(29): 22091-102
121. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 2012; Epub ahead of print
122. Sehgal N, Gupta A, Valli RK, et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 2012; 109(9): 3510-15
123. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 2012; 31(1): 151-65
124. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488(7409): 96-9
125. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009; 30(3): 337-52
126. Sagare AP, Deane R, Zetterberg H, et al. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 2011; 24(1): 25-34
127. Sutcliffe JG, Hedlund PB, Thomas EA, et al. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011; 89(6): 808-14